Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sialyl Lewis-keyhole limpet hemocyanin conjugate vaccine
- Development stage
- Phase 1
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The sialyl Lewis-keyhole limpet hemocyanin (KLH) conjugate vaccine is an investigational cancer immunotherapy designed to induce an immune response against tumor cells expressing the carbohydrate antigen sialyl Lewis a (CA19-9). The vaccine consists of the oligosaccharide antigen sialyl Lewis a chemically linked to KLH, a nonspecific immunomodulator. Upon administration—typically with the adjuvant QS-21—the vaccine stimulates production of IgG and IgM antibodies targeting the tumor-associated carbohydrate antigen. This immune response may trigger antibody-dependent cell-mediated cytotoxicity (ADCC) against cancer cells expressing the target antigen. Clinical trials have demonstrated that this approach is safe and immunogenic in humans, particularly in patients with metastatic breast cancer[2][3][5][6]. The primary indication under investigation has been breast cancer; however, broader applications in oncology are being explored.
- Other names
- sialyl Lewis a-keyhole limpet hemocyanin conjugate vaccineCA19-9-KLH vaccineCA-19-9-KLH vaccineCA 19-9-KLH vaccine
02
Targets
CA19-9 (Carbohydrate antigen 19-9)
Beyond the preview
Go deeper on sialyl Lewis-keyhole limpet hemocyanin conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sialyl Lewis-keyhole limpet hemocyanin conjugate vaccine.